These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 29732733)

  • 21. Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study.
    Ponseti JM; Azem J; Fort JM; Codina A; Montoro JB; Armengol M
    Clin Neurol Neurosurg; 2005 Apr; 107(3):187-90. PubMed ID: 15823673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Steroids and immunosuppressant drugs in myasthenia gravis.
    Sathasivam S
    Nat Clin Pract Neurol; 2008 Jun; 4(6):317-27. PubMed ID: 18493241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term treatment of myasthenia gravis with immunoadsorption.
    Haas M; Mayr N; Zeitlhofer J; Goldammer A; Derfler K
    J Clin Apher; 2002; 17(2):84-7. PubMed ID: 12210711
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prednisolone-sparing effect of cyclosporin A therapy for very elderly patients with myasthenia gravis.
    Nakamura S; Kaneko S; Shinde A; Morita J; Fujita K; Nakano S; Kusaka H
    Neuromuscul Disord; 2013 Feb; 23(2):176-9. PubMed ID: 23237872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: clinical features and therapeutic response.
    Mittal MK; Barohn RJ; Pasnoor M; McVey A; Herbelin L; Whittaker T; Dimachkie M
    J Clin Neuromuscul Dis; 2011 Sep; 13(1):46-52. PubMed ID: 22361625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonmelanoma skin cancer risk awareness in azathioprine-treated myasthenia gravis patients.
    McGurgan IJ; McGuigan C
    Brain Behav; 2015 Oct; 5(10):e00396. PubMed ID: 26516615
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment pathways in an inception lupus cohort over the first three years.
    Hanly JG; Sayani A; Doucette S; Iczkovitz S; Terres JAR
    Lupus; 2017 Feb; 26(2):119-124. PubMed ID: 27365369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of malignancy in myasthenia gravis patients exposed to azathioprine therapy for a median period of 3 years.
    Rawoot A; Little F; Heckmann JM
    S Afr Med J; 2006 Dec; 96(12):1249-51. PubMed ID: 17252153
    [No Abstract]   [Full Text] [Related]  

  • 29. Childhood onset myasthenia gravis.
    Raksadawan N; Kankirawatana P; Balankura K; Prateepratana P; Sangruchi T; Atchaneeyasakul LO
    J Med Assoc Thai; 2002 Aug; 85 Suppl 2():S769-77. PubMed ID: 12403259
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunosuppressive therapies in myasthenia gravis.
    Sanders DB; Evoli A
    Autoimmunity; 2010 Aug; 43(5-6):428-35. PubMed ID: 20166870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. COVID-19 in patients with myasthenia gravis: Epidemiology and disease course.
    Businaro P; Vaghi G; Marchioni E; Diamanti L; Arceri S; Bini P; Colombo E; Cosentino G; Alfonsi E; Costa A; Ravaglia S; Mallucci G; Ballante E; Franciotta D; Gastaldi M
    Muscle Nerve; 2021 Aug; 64(2):206-211. PubMed ID: 34031902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Myasthenia gravis. Opportunistic cytomegalovirus infection after long-term azathioprine therapy].
    Eisensehr I; Büttner U; Witt TN; von Appen K; Spuler S
    Nervenarzt; 1999 Oct; 70(10):924-6. PubMed ID: 10554786
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tacrolimus in refractory patients with myasthenia gravis: coadministration and tapering of oral prednisolone.
    Shimojima Y; Matsuda M; Gono T; Ishii W; Tokuda T; Ikeda S
    J Clin Neurosci; 2006 Jan; 13(1):39-44. PubMed ID: 16307880
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mycophenolate mofetil in the therapy of severe myasthenia gravis.
    Schneider C; Gold R; Reiners K; Toyka KV
    Eur Neurol; 2001; 46(2):79-82. PubMed ID: 11528156
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A case of myasthenia gravis, who developed minimal change nephrotic syndrome during immunosuppressive therapy after thymectomy].
    Takahashi K; Inoue Y; Matsuda O; Takemura T; Yoshimura A
    Nihon Jinzo Gakkai Shi; 2000 Jul; 42(5):394-8. PubMed ID: 10998921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Demographic and clinical characteristics of patients with myasthenia gravis].
    Rastenyte D; Vaitkus A; Neverauskas R; Pauza V
    Medicina (Kaunas); 2002; 38(6):611-6. PubMed ID: 12474667
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Azathioprine as a single immunosuppressive drug in the treatment of myasthenia gravis.
    Cosi V; Lombardi M; Erbetta A; Piccolo G
    Acta Neurol (Napoli); 1993 Apr; 15(2):123-31. PubMed ID: 8328322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improvement with rituximab in a patient with both rheumatoid arthritis and myasthenia gravis.
    Kerkeni S; Marotte H; Miossec P
    Muscle Nerve; 2008 Oct; 38(4):1343-5. PubMed ID: 18816604
    [No Abstract]   [Full Text] [Related]  

  • 39. [Myasthenia gravis in the elderly: diagnosis, comorbidity and course: 45 cases].
    Fraisse T; Labauge P; Camu W; Arlaud P; de Wazières B
    Presse Med; 2007 Jan; 36(1 Pt 1):9-14. PubMed ID: 17261443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of patients' pre-treatment expectations on immunosuppressive treatment outcomes in myasthenia gravis: A pilot correlational study.
    Frisaldi E; Ferrero B; Di Liberto A; Barbiani D; Camerone EM; Piedimonte A; Vollert J; Cavallo R; Zibetti M; Lopiano L; Shaibani A; Benedetti F
    Muscle Nerve; 2024 Sep; 70(3):413-419. PubMed ID: 38940302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.